Mitchell Chan
Known title: Chief Financial OfficerCIK: 0001789335
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program. Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.
Transaction History
| RGNX | ▼ Sell | Tax Withholding | 4,902 | $46K | 9/1/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 3,167 | $72K | 5/6/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 3,166 | — | 3/28/2026 | View on chart |
| RGNX | ▲ Buy | Grant | 73,749 | $0 | 1/6/2026 | View on chart |
| RGNX | ▼ Sell | Tax Withholding | 4,901 | $44K | 9/1/2025 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 3,167 | — | 3/28/2025 | View on chart |
| RGNX | ▲ Buy | Grant | 58,869 | $0 | 9/16/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
RGNX Reports Positive 3-Year Data and Settles Patent Litigation
RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.
RGNX Reports Positive 3-Year Data and Settles Patent Litigation. RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.